Drug Delivery Systems: National Institutes of Health Getting Drugs to Their Targets in a Controlled Manner
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Journal of Controlled Release 161 (2012) 446–460
Journal of Controlled Release 161 (2012) 446–460 Contents lists available at SciVerse ScienceDirect Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel Review Administration, distribution, metabolism and elimination of polymer therapeutics Ela Markovsky, Hemda Baabur-Cohen, Anat Eldar-Boock, Liora Omer, Galia Tiram, Shiran Ferber, Paula Ofek, Dina Polyak, Anna Scomparin, Ronit Satchi-Fainaro ⁎ Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel article info abstract Article history: Polymer conjugation is an efficient approach to improve the delivery of drugs and biological agents, both by Received 6 September 2011 protecting the body from the drug (by improving biodistribution and reducing toxicity) and by protecting the Accepted 16 December 2011 drug from the body (by preventing degradation and enhancing cellular uptake). This review discusses the Available online 29 December 2011 journey that polymer therapeutics make through the body, following the ADME (absorption, distribution, metabolism, excretion) concept. The biological factors and delivery system parameters that influence each Keywords: stage of the process will be described, with examples illustrating the different solutions to the challenges Polymer therapeutics Angiogenesis of drug delivery systems in vivo. ADME © 2011 Elsevier B.V. All rights reserved. Biodistribution Angiogenesis-dependent diseases Cancer Contents 1. Introduction ............................................................. -
An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: a Review
Muthadi Radhika Reddy /J. Pharm. Sci. & Res. Vol. 12(7), 2020, 925-940 An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review Muthadi Radhika Reddy1* 1School of pharmacy, Gurunanak Institute of Technical Campus, Hyderabad, Telangana, India and Department of Pharmacy, Gandhi Institute of Technology and Management University, Vizag, Andhra Pradesh, India INTRODUCTION 2. Useful in situations where rapid onset of action Fast dissolving drug delivery systems were first developed required such as in motion sickness, allergic attack, in the late 1970s as an alternative to conventional dosage coughing or asthma forms. These systems consist of solid dosage forms that 3. Has wide range of applications in pharmaceuticals, Rx disintegrate and dissolve quickly in the oral cavity without Prescriptions and OTC medications for treating pain, the need of water [1]. Fast dissolving drug delivery cough/cold, gastro-esophageal reflux disease,erectile systems include orally disintegrating tablets (ODTs) and dysfunction, sleep disorders, dietary supplements, etc oral thin films (OTFs). The Centre for Drug Evaluation [4] and Research (CDER) defines ODTs as,“a solid dosage 4. No water is required for the administration and hence form containing medicinal substances which disintegrates suitable during travelling rapidly, usually within a matter of seconds, when placed 5. Some drugs are absorbed from the mouth, pharynx upon the tongue” [2]. USFDA defines OTFs as, “a thin, and esophagus as the saliva passes down into the flexible, non-friable polymeric film strip containing one or stomach, enhancing bioavailability of drugs more dispersed active pharmaceutical ingredients which is 6. May offer improved bioavailability for poorly water intended to be placed on the tongue for rapid soluble drugs by offering large surface area as it disintegration or dissolution in the saliva prior to disintegrates and dissolves rapidly swallowing for delivery into the gastrointestinal tract” [3]. -
An Overview On: Sublingual Route for Systemic Drug Delivery
International Journal of Research in Pharmaceutical and Biomedical Sciences ISSN: 2229-3701 __________________________________________Review Article An Overview on: Sublingual Route for Systemic Drug Delivery K. Patel Nibha1 and SS. Pancholi2* 1Department of Pharmaceutics, BITS Institute of Pharmacy, Gujarat Technological university, Varnama, Vadodara, Gujarat, India 2BITS Institute of Pharmacy, Gujarat Technological University, Varnama, Vadodara, Gujarat, India. __________________________________________________________________________________ ABSTRACT Oral mucosal drug delivery is an alternative and promising method of systemic drug delivery which offers several advantages. Sublingual literally meaning is ''under the tongue'', administrating substance via mouth in such a way that the substance is rapidly absorbed via blood vessels under tongue. Sublingual route offers advantages such as bypasses hepatic first pass metabolic process which gives better bioavailability, rapid onset of action, patient compliance , self-medicated. Dysphagia (difficulty in swallowing) is common among in all ages of people and more in pediatric, geriatric, psychiatric patients. In terms of permeability, sublingual area of oral cavity is more permeable than buccal area which is in turn is more permeable than palatal area. Different techniques are used to formulate the sublingual dosage forms. Sublingual drug administration is applied in field of cardiovascular drugs, steroids, enzymes and some barbiturates. This review highlights advantages, disadvantages, different sublingual formulation such as tablets and films, evaluation. Key Words: Sublingual delivery, techniques, improved bioavailability, evaluation. INTRODUCTION and direct access to systemic circulation, the oral Drugs have been applied to the mucosa for topical mucosal route is suitable for drugs, which are application for many years. However, recently susceptible to acid hydrolysis in the stomach or there has been interest in exploiting the oral cavity which are extensively metabolized in the liver. -
Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
pharmaceutics Review Liposome-Based Drug Delivery Systems in Cancer Immunotherapy Zili Gu 1 , Candido G. Da Silva 1 , Koen van der Maaden 2,3, Ferry Ossendorp 2 and Luis J. Cruz 1,* 1 Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands 2 Tumor Immunology Group, Department of Immunology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands 3 TECOdevelopment GmbH, 53359 Rheinbach, Germany Received: 1 October 2020; Accepted: 2 November 2020; Published: 4 November 2020 Abstract: Cancer immunotherapy has shown remarkable progress in recent years. Nanocarriers, such as liposomes, have favorable advantages with the potential to further improve cancer immunotherapy and even stronger immune responses by improving cell type-specific delivery and enhancing drug efficacy. Liposomes can offer solutions to common problems faced by several cancer immunotherapies, including the following: (1) Vaccination: Liposomes can improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells; (2) Tumor normalization: Liposomes can deliver drugs selectively to the tumor microenvironment to overcome the immune-suppressive state; (3) Rewiring of tumor signaling: Liposomes can be used for the delivery of specific drugs to specific cell types to correct or modulate pathways to facilitate better anti-tumor immune responses; (4) Combinational therapy: Liposomes are ideal vehicles for the simultaneous delivery of drugs to be combined with other therapies, including chemotherapy, radiotherapy, and phototherapy. In this review, different liposomal systems specifically developed for immunomodulation in cancer are summarized and discussed. Keywords: liposome; drug delivery; cancer immunotherapy; immunomodulation 1. The Potential of Immunotherapy for the Treatment of Cancer Cancer immunotherapy has been widely explored because of its durable and robust effects [1]. -
Intra-Luminal Focused Ultrasound for Augmentation of Gastrointestinal Drug Delivery
Editorial Page 1 of 2 Intra-luminal focused ultrasound for augmentation of gastrointestinal drug delivery Ezekiel Maloney1, Joo Ha Hwang2 1Department of Radiology, 2Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA, USA Correspondence to: Joo Ha Hwang, MD, PhD. Division of Gastroenterology, Department of Medicine, University of Washington, Box 359773, 325 Ninth Avenue, Seattle, WA 98104, USA. Email: [email protected]. Provenance: This is a Guest Editorial commissioned by Section Editor Hui Kong, MD, PhD (Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China). Comment on: Schoellhammer CM, Schroeder A, Maa R, et al. Ultrasound-mediated gastrointestinal drug delivery. Sci Transl Med 2015;7:310ra168. Submitted Feb 01, 2017. Accepted for publication Feb 06, 2017. doi: 10.21037/atm.2017.03.42 View this article at: http://dx.doi.org/10.21037/atm.2017.03.42 The recent article by Schoellhammer et al., “Ultrasound- intensity ultrasound frequencies followed by quantification mediated gastrointestinal drug delivery” primarily of delivery of permeants (e.g., glucose, dextran, insulin). addresses practical limitations in drug delivery for medical Treated tissues showed enhanced transport. Similar management of inflammatory bowel disease (IBD), and findings were demonstrated in small and large bowel tissue presents pre-clinical data demonstrating that intra- for radiolabeled mesalamine and hydrocortisone. With 1 luminal, sub-ablative focused ultrasound (FUS), delivered minute of ultrasound treatment time, 3–5-fold improved via a trans-rectal transducer, can overcome some of these drug delivery was observed versus control. Additional limitations (1). The clinical application and benefit of such a ex vivo experiments utilizing variable FUS protocols to device is clear. -
Chapter 1 Controlling Drug Delivery
chapter 1 Controlling drug delivery Overview In this chapter we will: & differentiate drug delivery systems according to their physical state & differentiate drug delivery systems according to their route of administration & differentiate drug delivery systems according to their type of drug release & discuss drug transport across epithelial barriers. Introduction KeyPoints & Continued developments in Pharmacotherapy can be defined as the treatment chemistry, molecular biology and prevention of illness and disease by means of and genomics support the drugs of chemical or biological origin. It ranks discovery and developments among the most important methods of medical of new drugs and new drug treatment, together with surgery, physical targets. & treatment, radiation and psychotherapy. There The drug delivery system are many success stories concerning the use of employed can control the pharmacological action of a drugs and vaccines in the treatment, prevention drug, influencing its and in some cases even eradication of diseases pharmacokinetic and (e.g. smallpox, which is currently the only subsequent therapeutic human infectious disease completely profile. eradicated). Although it is almost impossible to estimate the exact extent of the impact of pharmacotherapy on human health, there can be no doubt that pharmacotherapy, together with improved sanitation, better diet and better housing, has improved people’s health, life expectancy and quality of life. Tip Unprecedented developments in genomics Combinatorial chemistry is a way to and molecular biology today offer a plethora of build a variety of structurally related new drug targets. The use of modern chemical drug compounds rapidly and synthetic methods (such as combinatorial systematically. These are assembled chemistry) enables the syntheses of a large from a range of molecular entities number of new drug candidates in shorter times which are put together in different ‘ ’ than ever before. -
Brain-Targeted Drug Delivery by Manipulating Protein Corona Functions
ARTICLE https://doi.org/10.1038/s41467-019-11593-z OPEN Brain-targeted drug delivery by manipulating protein corona functions Zui Zhang1,2, Juan Guan1, Zhuxuan Jiang1, Yang Yang1, Jican Liu3, Wei Hua4, Ying Mao4, Cheng Li2, Weiyue Lu2, Jun Qian2 & Changyou Zhan 1,2 Protein corona presents a major obstacle to bench-to-bedside translation of targeted drug delivery systems, severely affecting targeting yields and directing unfavorable biodistribution. 1234567890():,; Corona-mediated targeting provides a new impetus for specific drug delivery by precisely manipulating interaction modes of functional plasma proteins on nano-surface. Here bio- inspired liposomes (SP-sLip) were developed by modifying liposomal surface with a short nontoxic peptide derived from Aβ1-42 that specifically interacts with the lipid-binding domain of exchangeable apolipoproteins. SP-sLip absorb plasma apolipoproteins A1, E and J, con- sequently exposing receptor-binding domain of apolipoproteins to achieve brain-targeted delivery. Doxorubicin loaded SP-sLip (SP-sLip/DOX) show significant enhancement of brain distribution and anti-brain cancer effect in comparison to doxorubicin loaded plain liposomes. SP-sLip preserve functions of the absorbed human plasma ApoE, and the corona-mediated targeting strategy works in SP modified PLGA nanoparticles. The present study may pave a new avenue to facilitate clinical translation of targeted drug delivery systems. 1 Department of Pharmacology, School of Basic Medical Sciences & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, 200032 Shanghai, PR China. 2 School of Pharmacy & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, 201203 Shanghai, PR China. 3 Department of Pathology, Affiliated Zhongshan Hospital Qingpu Branch, Fudan University, 201700 Shanghai, PR China. -
Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs
pharmaceutics Review Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs Hua He 1,2, Dongfen Yuan 2 , Yun Wu 3 and Yanguang Cao 2,4,* 1 Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China; [email protected] 2 Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Department of Biomedical Engineering, University at Buffalo, The State University of New York, 332 Bonner Hall, Buffalo, NY 14260, USA; [email protected] 4 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA * Correspondence: [email protected]; Tel.: +1-(919)-966-4040 Received: 30 January 2019; Accepted: 28 February 2019; Published: 7 March 2019 Abstract: Liposomal formulations have been developed to improve the therapeutic index of encapsulated drugs by altering the balance of on- and off-targeted distribution. The improved therapeutic efficacy of liposomal drugs is primarily attributed to enhanced distribution at the sites of action. The targeted distribution of liposomal drugs depends not only on the physicochemical properties of the liposomes, but also on multiple components of the biological system. Pharmacokinetic–pharmacodynamic (PK–PD) modeling has recently emerged as a useful tool with which to assess the impact of formulation- and system-specific factors on the targeted disposition and therapeutic efficacy of liposomal drugs. The use of PK–PD modeling to facilitate the development and regulatory reviews of generic versions of liposomal drugs recently drew the attention of the U.S. -
Review On: Sublingual Route for Systemic Drug Delivery
IAJPS 2018, 05 (01), 453-462 Himanshi Rathaur and G.Gnanarajan ISSN 2349-7750 CODEN [USA]: IAJPBB ISSN: 2349-7750 INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES http://doi.org/10.5281/zenodo.1161209 Available online at: http://www.iajps.com Review Article REVIEW ON: SUBLINGUAL ROUTE FOR SYSTEMIC DRUG DELIVERY Himanshi Rathaur*1and G.Gnanarajan2 *1Shri Guru Ram Rai Institute of Technology and Sciences, Department of Pharmaceutics, Uttarakhand Technical University, Dehradun,248001, Uttarakhand, India 2Shri Guru Ram Rai Institute of Technology and Sciences, Department of Pharmaceutics, Faculty of Pharmacy, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India. Abstract: Delivery of drug in the oral cavity through the oral mucosa is examined to be a promising alternative to the oral route. Sublingual means “under the tongue” which rapidly absorb the drug through the oral mucosa and enter into the systemic circulation. This route provides various advantages such as quick onset of action, patient compliance, hepatic first pass metabolism and increase bioavailability. Dysphagia is a common problem in pediatric, geriatric and psychiatric patients. In terms of permeability sublingual area of oral cavity is more permeable than buccal area which is in turn is more permeable than palatal area. Now a days most of the population need effective, faster and better relief within a short period of time. So, this route is the most appropriate route of administration and it rapidly dissolves in saliva. Many drugs like cardiovascular drugs, steroids, -
1097.Full.Pdf
1521-009X/47/10/1097–1099$35.00 https://doi.org/10.1124/dmd.119.088708 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 47:1097–1099, October 2019 Copyright ª 2019 by The American Society for Pharmacology and Experimental Therapeutics Special Section on Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities—Commentary Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities Brooke M. Rock and Robert S. Foti Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, California (B.M.R.) and Pharmacokinetics and Drug Metabolism, Amgen Research, Cambridge, Massachusetts (R.S.F.) Received July 10, 2019; accepted July 26, 2019 Downloaded from ABSTRACT The discovery and development of novel pharmaceutical therapies in experimental and analytical tools will become increasingly is rapidly transitioning from a small molecule–dominated focus to evident, both to increase the speed and efficiency of identifying safe a more balanced portfolio consisting of small molecules, mono- and efficacious molecules and simultaneously decreasing our de- clonal antibodies, engineered proteins (modified endogenous pro- pendence on in vivo studies in preclinical species. The research and dmd.aspetjournals.org teins, bispecific antibodies, and fusion proteins), oligonucleotides, commentary included in this special issue will provide researchers, and gene-based therapies. This commentary, and the special issue clinicians, and the patients we serve more options in the ongoing as a whole, aims to highlight -
A Guide to Aerosol Delivery Devices for Respiratory Therapists 4Th Edition
A Guide To Aerosol Delivery Devices for Respiratory Therapists 4th Edition Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Dave Burnett, PhD, RRT, AE-C Shawna Strickland, PhD, RRT-NPS, RRT-ACCS, AE-C, FAARC Timothy R. Myers, MBA, RRT-NPS, FAARC Platinum Sponsor Copyright ©2017 by the American Association for Respiratory Care A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4th Edition Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Dave Burnett, PhD, RRT, AE-C Shawna Strickland, PhD, RRT-NPS, RRT-ACCS, AE-C, FAARC Timothy R. Myers, MBA, RRT-NPS, FAARC With a Foreword by Timothy R. Myers, MBA, RRT-NPS, FAARC Chief Business Officer American Association for Respiratory Care DISCLOSURE Douglas S. Gardenhire, EdD, RRT-NPS, FAARC has served as a consultant for the following companies: Westmed, Inc. and Boehringer Ingelheim. Produced by the American Association for Respiratory Care 2 A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4th Edition American Association for Respiratory Care, © 2017 Foreward Aerosol therapy is considered to be one of the corner- any) benefit from their prescribed metered-dose inhalers, stones of respiratory therapy that exemplifies the nuances dry-powder inhalers, and nebulizers simply because they are of both the art and science of 21st century medicine. As not adequately trained or evaluated on their proper use. respiratory therapists are the only health care providers The combination of the right medication and the most who receive extensive formal education and who are tested optimal delivery device with the patient’s cognitive and for competency in aerosol therapy, the ability to manage physical abilities is the critical juncture where science inter- patients with both acute and chronic respiratory disease as sects with art. -
Membranes and Barriers: Targeted Drug Delivery,” and Details of Those Studies Can Be Found in This Monograph
National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Membranes and Barriers: Targeted Drug Delivery U.S. Department of Health and Human Services1 • Public5 Health Service4 • National Institutes of Health Membranes and Barriers: Targeted Drug Delivery Editor: Rao S. Rapaka, Ph.D. NIDA Research Monograph 154 1995 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse Division of Preclinical Research 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT This monograph is based on the papers from a technical review on “Membranes and Barriers: Targeted Drug Delivery” held on September 28-29, 1993. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.